Maintaining bone mass by bisphosphonate incadronate disodium (YM175) sequential treatment after discontinuation of intermittent human parathyroid hormone (1-34) administration in ovariectomized rats.

Takano Y, Tanizawa T, Mashiba T, Endo N, Nishida S, Takahashi HE

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Feb 1996Cited by 28 (Europe PMC)

PMID8822340DOI10.1002/jbmr.5650110205PepBankPUB-08822340

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, PTH restored bone mass to sham control levels.
In plain wordsIn ovariectomized rats, PTH restored bone mass to levels in sham-operated controls.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone mass restoration
Study
Ratn: not reported in source
Ovariectomized Sprague-Dawley rats
Comparator
Sham controls
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg three times a week · subcutaneous · 8 weeksAs given in this study (Rat).
Source sentences
Summary
The results of microstructural assessment in proximal tibial metaphysis and bone mineral density in distal and proximal femur demonstrated that PTH treatment for 8 weeks restored bone mass to the sham control level.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighty-eight 11-week-old Sprague-Dawley rats were divided into sham operation and OVX groups.
Summary · context
The OVX rats were treated for 8 weeks with the subcutaneous intermittent injection of 30 micrograms/kg of hPTH(1-34) three times a week beginning 4 weeks after surgery, then PTH treatment was withdrawn and YM175 (10 micrograms/kg) was injected subcutaneously three times a week for 4 weeks.
Summary · context
YM175 treatment was withdrawn for the last 8 weeks of the protocol.
Report a problemFND-0882234001
02AnimalAnimal study (in vivo)Efficacy outcome
In rats, PTH-induced tibial cancellous bone mass decreased after withdrawal and subsequently almost disappeared.
In plain wordsIn rats, spongy bone gained during PTH treatment declined after PTH stopped and later almost disappeared.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTibial cancellous bone mass after withdrawal
Study
Ratn: not reported in source
Ovariectomized Sprague-Dawley rats
Comparator
End of PTH treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg three times a week · subcutaneous · 8 weeksAs given in this study (Rat).
Source sentences
Summary
However, after cessation of PTH treatment, the PTH-induced tibial cancellous bone mass showed a decrease at 4 weeks and almost totally disappeared after 12 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighty-eight 11-week-old Sprague-Dawley rats were divided into sham operation and OVX groups.
Summary · context
The OVX rats were treated for 8 weeks with the subcutaneous intermittent injection of 30 micrograms/kg of hPTH(1-34) three times a week beginning 4 weeks after surgery, then PTH treatment was withdrawn and YM175 (10 micrograms/kg) was injected subcutaneously three times a week for 4 weeks.
Summary · context
YM175 treatment was withdrawn for the last 8 weeks of the protocol.
Report a problemFND-0882234002
03AnimalAnimal study (in vivo)Efficacy outcome
In rats, cortical bone was not lost during PTH treatment.
In plain wordsIn rats, cortical bone did not decline during PTH treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCortical bone loss during treatment
Study
Ratn: not reported in source
Ovariectomized Sprague-Dawley rats
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
30 micrograms/kg three times a week · subcutaneous · 8 weeksAs given in this study (Rat).
Source sentences
Summary
Cortical bone was not lost during PTH treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighty-eight 11-week-old Sprague-Dawley rats were divided into sham operation and OVX groups.
Summary · context
The OVX rats were treated for 8 weeks with the subcutaneous intermittent injection of 30 micrograms/kg of hPTH(1-34) three times a week beginning 4 weeks after surgery, then PTH treatment was withdrawn and YM175 (10 micrograms/kg) was injected subcutaneously three times a week for 4 weeks.
Summary · context
YM175 treatment was withdrawn for the last 8 weeks of the protocol.
Report a problemFND-0882234004

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

04AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Efficacy outcome
In rats, sequential YM175 maintained PTH-induced tibial cancellous bone, including after YM175 withdrawal.
In plain wordsIn rats, YM175 maintained spongy bone gained with PTH, including after YM175 stopped, compared with PTH withdrawal alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone maintenance with YM175
Study
Ratn: not reported in source
Ovariectomized Sprague-Dawley rats
Comparator
PTH withdrawal without YM175
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Conversely, YM175 treatment maintained the PTH-induced tibial cancellous bone mass, and the bone continued to be maintained after 8 weeks of withdrawal of the YM175.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighty-eight 11-week-old Sprague-Dawley rats were divided into sham operation and OVX groups.
Summary · context
The OVX rats were treated for 8 weeks with the subcutaneous intermittent injection of 30 micrograms/kg of hPTH(1-34) three times a week beginning 4 weeks after surgery, then PTH treatment was withdrawn and YM175 (10 micrograms/kg) was injected subcutaneously three times a week for 4 weeks.
Summary · context
YM175 treatment was withdrawn for the last 8 weeks of the protocol.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0882234003
05AnimalNot a test of Teriparatide (PTH 1-34) aloneAnimal study (in vivo)Mechanism
In rats, sequential YM175 maintained PTH-induced cancellous bone by suppressing remodeling.
In plain wordsIn rats, YM175 maintained spongy bone gained with PTH by reducing bone remodeling.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseRemodeling suppression with sequential YM175
Study
Ratn: not reported in source
Ovariectomized Sprague-Dawley rats
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
YM175 maintained the PTH-induced new tibial cancellous bone in OVX rats by suppressing remodeling.
3 context sentences(design, population, supporting numbers)
Summary · context
Eighty-eight 11-week-old Sprague-Dawley rats were divided into sham operation and OVX groups.
Summary · context
The OVX rats were treated for 8 weeks with the subcutaneous intermittent injection of 30 micrograms/kg of hPTH(1-34) three times a week beginning 4 weeks after surgery, then PTH treatment was withdrawn and YM175 (10 micrograms/kg) was injected subcutaneously three times a week for 4 weeks.
Summary · context
YM175 treatment was withdrawn for the last 8 weeks of the protocol.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-0882234005

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.